In early October 2025, Airship AI Holdings announced it was awarded 16 contracts totaling US$11.0 million from the US Department of Justice and Department of Homeland Security to provide AI-driven surveillance solutions for public safety and investigations.
The selection of Airship AI's Outpost AI platform, following successful pilot deployments that replaced prior systems, highlights increasing federal confidence in the company's proprietary threat detection technology.
We'll examine how...
Biomea Fusion, Inc. recently announced positive 52-week results from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes, reporting statistically significant and clinically meaningful reductions in HbA1c, especially for patients with severe insulin-deficient diabetes and those not reaching glycemic targets on GLP-1 therapy.
The favorable safety profile and planned next steps, including additional trials and ongoing studies, highlight the company’s continued progress in...
Recently, news highlighted that Cable One is facing sluggish subscriber trends and a projected sales decline, pointing to deteriorating business performance in the most recent quarter.
An important insight is that continued operational and financial headwinds, especially from weakening subscriber growth, have amplified investor concerns regarding the company's outlook and risk profile.
We'll examine how these slowing subscriber additions and anticipated revenue declines may reshape Cable...
This week’s picks cover: How AMD’s OpenAI partnership could ignite a re-rating, why IREN Energy is in phase 3 of a 4-phase transformation to a profitable powerhouse, and how PWR Holdings turned F1 dominance into a springboard for aerospace and EV growth
If you have been watching GoodRx Holdings lately, you are probably weighing whether its current price reflects a hidden bargain or just more risk. At $4.39, the stock has certainly traveled a bumpy road. Despite a nice pop of nearly 4% over the last week, and almost 10% across the past month, the longer-term chart remains tough to ignore. Down roughly 37% over the last year and an eye-catching 92% since its five-year high, GoodRx has given investors moments of excitement mixed with plenty of...
If you're considering what to do with your Healthcare Realty Trust shares, or perhaps thinking about making a move, you're not alone. The stock has been making waves, sometimes subtle, sometimes more noticeable. Over just the past week, there was a minimal dip of -0.1%, and the past month has seen a slightly larger decline of -1.8%. Yet, zooming out, things look far sunnier: Healthcare Realty Trust is up 7.7% so far this year and a solid 9.5% over the last twelve months. Of course, anyone who...
If you’ve been tracking SiriusPoint’s stock, you know this isn’t one of those sleepwalking tickers. Whether you’re eyeing that impressive 259.4% gain over the last three years or sizing up this year’s 15.8% return, SiriusPoint has certainly kept things interesting for shareholders. Even with a slight dip over the last month, it’s clear that investors are reassessing the company’s growth prospects and its risk, potentially setting up for the next big move.
Much of the recent momentum seems...
Skye Bioscience (SKYE) has scheduled a special call to present topline data from its Phase 2a clinical trial of Nimacimab, focusing on both monotherapy and combination treatment. Updates like these frequently shape investor sentiment around development-stage biotech stocks.
See our latest analysis for Skye Bioscience.
Skye Bioscience’s latest topline clinical update arrives after a period of muted share price action. Its stock closed at $1.90 and has shown minimal momentum over recent months...
If you are looking for the next move on Soho House & Co stock, you have probably noticed its eye-catching trajectory. This is not a slow and steady story, but one with dramatic swings and the kind of big numbers that spark conversation. Just over the past year, Soho House & Co’s shares have surged 69.1%. If you stretch that lens out to three years, we are talking 114.5% growth, which is well beyond what most lifestyle or hospitality names can boast. Even in recent months, the stock has kept...
If you have been watching Rush Enterprises, you may be asking yourself whether now is the moment to buy, hold, or move on. The stock price has slipped by 7.3% in the past week and it is down more than 14% over the last month. Year to date, shares have shed 8.8%. On a longer horizon, however, Rush Enterprises has quietly put together an impressive run, climbing 70.8% over three years and more than doubling investors’ money over five years with a 114.6% gain. That kind of return turns heads,...
The Morning Bull - US Market Morning Update Tuesday, Oct, 7 2025
US stock futures are moving lower ahead of the open as persistent political uncertainty in both the US and Europe weighs on sentiment. With the US government shutdown showing no signs of resolution and French bond yields near multi-year highs because of fiscal and leadership gridlock, investors are focused on how these tensions could drive volatility and put pressure on areas of the market most sensitive to economic momentum and...
RBC Capital has reiterated its positive outlook for Brookfield Renewable, highlighting enhanced growth visibility and strong confidence in the company's long-term expansion plans following recent operational results.
Despite reporting lower-than-expected Q2 2025 profits, Brookfield Renewable saw a 10% year-over-year rise in Funds From Operations, driven largely by its hydropower and distributed energy businesses.
We'll examine how analyst confidence in Brookfield Renewable's operational...
On October 6, 2025, Senseonics Holdings announced preliminary unaudited revenue for the third quarter ended September 30, reporting approximately US$8.1 million, an increase of 91% over the same period in 2024, primarily attributed to roughly 160% new patient growth in the U.S.
This upturn in both revenue and new patient adoption highlights more robust market traction, suggesting a potential acceleration in demand for the company’s continuous glucose monitoring systems.
We’ll now explore how...
If you're standing at the crossroads of what to do with your Knife River shares or thinking of putting some capital to work, you're not alone. Knife River’s recent performance has grabbed the attention of both cautious investors and opportunists, sparking plenty of debate on whether the current price fairly reflects the company’s long-term prospects.
Knife River's stock price has seen a difficult stretch lately. Down 3.9% in the last week, 11.6% in the last month, and a hefty 29.2%...
AC Immune (NasdaqGM:ACIU) just shared peer-reviewed data from its Phase 1b/2a trial of ACI-35.030, an active immunotherapy targeting Tau in early Alzheimer's, developed with Janssen. The findings highlight a rapid and sustained antibody response as well as a clean safety profile.
See our latest analysis for AC Immune.
With this encouraging clinical update, AC Immune is starting to turn heads, especially as the company’s latest innovation underscores its growing potential in Alzheimer’s...
